Prospective Drug-Drug Interaction (PDDI)

PDDI logic engines classify interactions by their underlying biological mechanism to determine clinical significance.

• Pharmacokinetic (PK) Interactions: One drug alters the absorption, distribution, metabolism, or excretion (ADME) of another. The most critical involve the cytochrome P450 (CYP450) enzyme family, where inhibitors like fluconazole can drastically increase the serum concentration of substrates like warfarin, leading to toxicity.
• Pharmacodynamic (PD) Interactions: Two drugs act on the same physiological pathway, producing an additive, synergistic, or antagonistic effect. A classic example is the co-prescription of an SSRI and an MAOI, which can precipitate serotonin syndrome due to excessive serotonergic activity.
• Hybrid Interactions: Some interactions involve both pathways, such as the combination of ACE inhibitors and potassium-sparing diuretics, which pharmacodynamically elevate potassium while pharmacokinetic renal impairment reduces excretion.

To combat alert fatigue, modern PDDI systems implement tiered severity classifications that modulate the interruptive nature of the warning.

• Contraindicated (Level 1): The interaction is life-threatening and the combination should never be administered. These generate hard-stop alerts that block order completion.
• Major/Severe (Level 2): The interaction poses a high risk of serious adverse outcomes. These trigger interruptive pop-ups requiring a documented override reason.
• Moderate (Level 3): The interaction may exacerbate a condition or require monitoring. These are often displayed as non-interruptive, passive banners to avoid workflow disruption.
• Minor (Level 4): Evidence is limited or clinical impact is negligible. These are typically suppressed entirely or logged silently for retrospective analysis.
• Contextualization: Advanced systems integrate patient-specific variables like renal function (eGFR) and genetic markers to suppress alerts for interactions that are clinically irrelevant to the specific patient.

The accuracy of a PDDI system is directly dependent on the curation, granularity, and interoperability of its underlying drug knowledge base.

• Structured Product Labeling (SPL): The FDA mandates that prescribing information be encoded in XML-based SPL format, providing a machine-readable source for interaction data directly from manufacturers.
• Standardized Terminologies: Systems map proprietary drug lists to RxNorm for active ingredient normalization and SNOMED CT for clinical effect coding, enabling semantic interoperability across disparate EHRs.
• Content Vendors: Most institutions license third-party knowledge bases like Multum, First Databank (FDB), or Micromedex, which employ teams of clinical pharmacists to review primary literature and update interaction monographs.
• Custom Rule Authoring: High-maturity health systems augment vendor content with locally authored rules to address formulary-specific interactions or to suppress alerts for intentional therapeutic duplications (e.g., dual antiplatelet therapy).

Static rule checking is insufficient for complex polypharmacy. Advanced PDDI engines incorporate temporal logic to account for the longitudinal patient record.

• Active Ingredient Half-Life Logic: The system calculates whether a discontinued medication's active moiety is still physiologically relevant based on five half-lives before clearing the interaction flag.
• Sequential Interaction Prediction: Machine learning models analyze historical medication administration records (MARs) to predict the probability of a future interaction when a new drug is introduced into a complex regimen.
• Cumulative Burden Assessment: Instead of isolated pair-checking, the system evaluates the total anticholinergic burden or QTc-prolonging risk across all active orders, flagging a cumulative threshold breach even if no single pair triggers an alert.
• Metabolite Tracking: Pro-drugs and active metabolites are mapped to the parent compound to ensure that interactions are detected even when the interacting entity is a downstream metabolic product.

An injury resulting from medical intervention related to a drug. PDDI screening is a primary preventative control to stop ADEs before they occur.

• Preventable ADEs: Often start as a medication error or an undetected PDDI.
• Amplified Risk: Polypharmacy dramatically increases the statistical probability of an ADE.
• Clinical Impact: ADEs are a leading cause of iatrogenic patient harm, driving the regulatory mandate for automated interaction checks.

The desensitization of clinicians caused by excessive exposure to irrelevant or false-positive safety warnings. This is the primary failure mode of PDDI systems.

• Override Rate: Clinicians override up to 90% of drug interaction alerts if they are not clinically relevant.
• Signal-to-Noise: Effective PDDI logic must suppress noisy alerts (e.g., theoretical interactions) to preserve attention for critical signals.
• Consequence: High alert fatigue leads to clinicians ignoring even severe, life-threatening interaction warnings.

A probabilistic gate that routes AI-extracted medication data for human review only when the model's prediction score falls below a predefined certainty level.

• High Confidence: PDDI alerts with >95% certainty can be pushed directly to the pharmacy queue.
• Low Confidence: Ambiguous interactions (e.g., severity unclear due to missing labs) are routed to a clinical pharmacist for contextual review.
• Optimization: Balances the safety of Human-in-the-Loop (HITL) review with the efficiency of straight-through processing.

A normalized naming system for clinical drugs produced by the U.S. National Library of Medicine. It is the essential semantic backbone for accurate PDDI logic.

• Ingredient Linking: Resolves brand names (Tylenol) and generics (acetaminophen) to a single active ingredient identifier.
• Semantic Clinical Drug: Links active ingredients to specific dose forms, enabling precise interaction rule execution.
• Interoperability: Bridges disparate pharmacy databases that use proprietary drug identifiers, ensuring the PDDI engine checks a unified formulary.

The AI capability to chronologically sequence clinical events to validate the logical consistency of a medication timeline. Crucial for distinguishing active interactions from historical ones.

• Look-Back Windows: The system must reason if a discontinued MAO inhibitor is still biologically active when a new SSRI is ordered.
• Order Sequencing: Detects if a PDDI alert is triggered by a duplicate order placed seconds apart versus a genuine new interaction.
• Half-Life Awareness: Advanced systems factor in drug half-lives to determine if a recently stopped drug still poses a metabolic interaction risk.

A specific type of PDDI notification triggered when a new order is therapeutically equivalent to an existing active order, posing a risk of overdose.

• Mechanism: Relies on Active Ingredient Matching to link brand and generic formulations.
• Class Duplication: Advanced checks flag co-prescribing of two different drugs within the same therapeutic class (e.g., two NSAIDs).
• Clinical Significance: Prevents unintentional cumulative toxicity, such as acetaminophen overdose from combining a painkiller with a cold remedy.